IS7535A - Lyfjablanda - Google Patents

Lyfjablanda

Info

Publication number: IS7535A
Authority: IS; Iceland
Prior art keywords: composition; patient; macrocyclic; cyclic enhancer; hsieh
Prior art date: 2002-04-19

Application number

IS7535A

Other languages

English (en)

Other versions

IS2667B (is

Inventor

Gyurik Robert

Original Assignee

Auxilium Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-19

Filing date

2004-11-17

Publication date

2004-11-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7535(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-17 Application filed by Auxilium Pharmaceuticals, Inc. filed Critical Auxilium Pharmaceuticals, Inc.

2004-11-17 Publication of IS7535A publication Critical patent/IS7535A/is

2010-08-15 Publication of IS2667B publication Critical patent/IS2667B/is

Links

239000000203 mixture Substances 0.000 title abstract 6
125000004122 cyclic group Chemical group 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
239000003098 androgen Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
201000003585 eunuchism Diseases 0.000 abstract 1
150000002576 ketones Chemical class 0.000 abstract 1
208000037106 male hypogonadism Diseases 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000002562 thickening agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

IS7535A 2002-04-19 2004-11-17 Lyfjablanda sem inniheldur andrógen IS2667B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37410302P	2002-04-19	2002-04-19
PCT/US2003/012235 WO2003088974A1 (en)	2002-04-19	2003-04-21	Pharmaceutical composition

Publications (2)

Publication Number	Publication Date
IS7535A true IS7535A (is)	2004-11-17
IS2667B IS2667B (is)	2010-08-15

Family

ID=29251138

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IS7535A IS2667B (is)	2002-04-19	2004-11-17	Lyfjablanda sem inniheldur andrógen
IS8870A IS2946B (is)	2002-04-19	2010-01-06	Lyfjablanda sem felur í sér andrógen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IS8870A IS2946B (is)	2002-04-19	2010-01-06	Lyfjablanda sem felur í sér andrógen

Country Status (29)

Country	Link
US (21)	US7320968B2 (is)
EP (2)	EP1741433B1 (is)
JP (1)	JP2005519985A (is)
KR (2)	KR100977896B1 (is)
CN (2)	CN1662243B (is)
AR (2)	AR039644A1 (is)
AT (1)	ATE371456T1 (is)
AU (1)	AU2003228612B2 (is)
BR (1)	BR0309390A (is)
CA (1)	CA2470200C (is)
CY (1)	CY1109005T1 (is)
DE (1)	DE60315939T2 (is)
DK (1)	DK1425019T3 (is)
EA (1)	EA009839B1 (is)
EG (1)	EG24882A (is)
ES (2)	ES2399900T3 (is)
IL (1)	IL164547A (is)
IS (2)	IS2667B (is)
LT (1)	LT5235B (is)
LV (1)	LV13303B (is)
MX (1)	MXPA04010311A (is)
MY (1)	MY139721A (is)
NO (1)	NO335864B1 (is)
NZ (1)	NZ535970A (is)
PL (1)	PL213976B1 (is)
SA (1)	SA03240158B1 (is)
TW (1)	TWI362932B (is)
WO (1)	WO2003088974A1 (is)
ZA (1)	ZA200408422B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
US7244703B2 (en)	2001-06-22	2007-07-17	Bentley Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for peptide treatment
US20040072810A1 (en) *	2001-11-07	2004-04-15	Besins International Belgique	Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) *	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
US8883769B2 (en) *	2003-06-18	2014-11-11	White Mountain Pharma, Inc.	Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) *	2003-06-18	2004-12-23	White Hillary D.	Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
EA010885B1 (ru)	2003-12-08	2008-12-30	Бентли Фармасьютикалз, Инк.	Фармацевтические композиции и способы лечения инсулином
BRPI0515040B1 (pt) *	2004-09-09	2021-10-13	Besins Healthcare Luxembourg S.A.R.L	Géis de testosterona compreendendo propileno glicol como intensificador de penetração
EP1634583A1 (en) *	2004-09-09	2006-03-15	Laboratoires Besins International	Testosterone gels comprising propylene glycol as penetration enhancer
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
DK2450041T3 (en)	2005-10-12	2018-11-19	Unimed Pharmaceuticals Llc	Enhanced testosterone gel for use in the treatment of hypogonadism
EP2273974A2 (en) *	2008-05-09	2011-01-19	Tolmar, Inc.	Proguanil to treat skin/mucosal diseases
US20090324502A1 (en) *	2008-06-05	2009-12-31	Cpex Pharmaceuticals, Inc.	Nasal Formulations of Insulin
US20110097363A1 (en) *	2009-10-22	2011-04-28	Cpex Pharmaceuticals, Inc.	Therapeutically Effective Preparations of Insulin
AU2011329782A1 (en)	2010-11-18	2013-06-20	White Mountain Pharma, Inc.	Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20190117803A (ko) *	2011-05-15	2019-10-16	에이세러스 파마슈티칼즈 에스알엘	비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US10568905B2 (en) *	2012-02-14	2020-02-25	Metabolic Therapy Inc.	Pharmaceutical composition and method for treating retinal neurodegeneration
CA2868500C (en)	2012-04-06	2020-04-21	Antares Pharma, Inc.	Needle assisted jet injection administration of testosterone compositions
CA2885142A1 (en)	2012-09-20	2014-03-27	Leonard Austin Hensel	Lock ring spreader
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en)	2013-12-13	2014-07-22	Upsher-Smith Laboratories, Inc.	Testosterone gel compositions and related methods
US20170014417A1 (en)	2015-07-14	2017-01-19	Lipp Life Sciences Llc	Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) *	2017-11-02	2019-05-09	Rick Coulon	Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) *	2020-11-29	2022-11-04	山东大学	一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3989815A (en) *	1975-06-19	1976-11-02	Nelson Research & Development Company	Novel N-bis-azacyclopentan-2-onyl alkanes
US4405616A (en) *	1975-06-19	1983-09-20	Nelson Research & Development Company	Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) *	1975-06-19	1982-02-23	Nelson Research & Development Co.	Vehicle composition containing 1-substituted azacycloalkan-2-ones
BE843140A (fr) *	1975-06-19	1976-10-18		Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) *	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US3991203A (en) *	1975-06-19	1976-11-09	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4424210A (en) *	1980-04-04	1984-01-03	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) *	1980-04-04	1984-04-24	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4423040A (en) *	1980-04-04	1983-12-27	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4415563A (en) *	1980-04-04	1983-11-15	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclononan-2-ones
US5023252A (en) *	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5731303A (en)	1985-12-04	1998-03-24	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery compositions
US5270346A (en)	1986-01-31	1993-12-14	Whitby Research, Inc.	Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) *	1986-01-31	1991-02-12	Whitby Research, Inc.	Compositions comprising 1-substituted azacycloalkanes
US4801586A (en)	1986-04-23	1989-01-31	Nelson Research & Development Co.	Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en)	1987-09-30	1989-11-07	Nelson Research & Development Co.	Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en)	1988-03-08	1991-05-28	Warner-Lambert Company	Compositions with enhanced penetration
US5676968A (en) *	1991-10-31	1997-10-14	Schering Aktiengesellschaft	Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) *	1994-04-12	2001-02-20	Adolor Corporation	Methods for treating inflammatory conditions
GB9516268D0 (en) *	1995-08-08	1995-10-11	Danbiosyst Uk	Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de)	1996-05-02	1997-11-13	Jenapharm Gmbh	Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) *	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US6019997A (en) *	1997-01-09	2000-02-01	Minnesota Mining And Manufacturing	Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) *	1997-01-13	1998-07-16	Jenapharm Gmbh	Transdermales therapeutisches System
AU737053B2 (en) *	1997-01-30	2001-08-09	Novartis Ag	Oil-free pharmaceutical compositions containing cyclosporin A
DE29704393U1 (de) *	1997-03-11	1997-07-17	Aesculap Ag, 78532 Tuttlingen	Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) *	1997-10-16	1999-10-19	Macrochem Corporation	Hormone replacement therapy drug formulations for topical application to the skin
ATE418988T1 (de) *	1997-11-10	2009-01-15	Strakan Int Ltd	Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
US6980952B1 (en) *	1998-08-15	2005-12-27	Texas Instruments Incorporated	Source normalization training for HMM modeling of speech
EP1031564A1 (en) *	1999-02-26	2000-08-30	Klinge Pharma GmbH	Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) *	1999-11-30	2003-06-27	Pf Medicament	Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
ES2299441T3 (es) *	1999-12-08	2008-06-01	Pharmacia Corporation	Forma en estado solido de celecoxib con biodisponibilidad potenciada.
US6495124B1 (en)	2000-02-14	2002-12-17	Macrochem Corporation	Antifungal nail lacquer and method using same
CA2418135C (en) *	2000-08-03	2011-09-20	Antares Pharma Ipl Ag	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) *	2003-03-11	2004-10-07	Carrara Dario Norberto R.	Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) *	2000-08-03	2007-04-03	Antares Pharma Ipl Ag	Formulations for transdermal or transmucosal application
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
CA2419573C (en) *	2000-08-30	2007-04-03	Unimed Pharmaceuticals, Inc.	Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) *	2000-08-30	2004-01-01	Dudley Robert E.	Androgen pharmaceutical composition and method for treating depression
PT1315502E (pt)	2000-08-30	2010-05-06	Unimed Pharmaceuticals Llc	Método para tratar a disfunção eréctil e para aumentar a líbido em homens
US6743448B2 (en) *	2000-12-11	2004-06-01	Abraham H. Kryger	Topical testosterone formulations and associated methods
EP1347764B1 (de) *	2000-12-22	2007-03-14	Dr. August Wolff GmbH & Co. KG Arzneimittel	Gelzusammensetzung auf alkoholischer basis zur behandlung von hypogonadismus durch transskrotale applikation
US20030027833A1 (en) *	2001-05-07	2003-02-06	Cleary Gary W.	Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en)	2001-06-27	2003-02-06	Van Der Hoop Roland Gerritsen	Therapeutic combinations for the treatment of hormone deficiencies
US7169107B2 (en) *	2002-01-25	2007-01-30	Karen Jersey-Willuhn	Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system
AU2003228314C1 (en)	2002-03-15	2009-03-26	Besins Healthcare Luxembourg Sarl	Androgen pharmaceutical composition and method for treating depression
MY139721A (en)	2002-04-19	2009-10-30	Cpex Pharmaceuticals Inc	Pharmaceutical composition
US20040259784A1 (en) *	2003-06-18	2004-12-23	White Hillary D.	Compositions and methods for treatment of muscle pain and muscle wasting

2003
- 2003-04-18 MY MYPI20031462A patent/MY139721A/en unknown
- 2003-04-19 EG EG2003040351A patent/EG24882A/xx active
- 2003-04-21 EA EA200401410A patent/EA009839B1/ru not_active IP Right Cessation
- 2003-04-21 US US10/473,724 patent/US7320968B2/en not_active Expired - Lifetime
- 2003-04-21 AU AU2003228612A patent/AU2003228612B2/en not_active Ceased
- 2003-04-21 CN CN038142368A patent/CN1662243B/zh not_active Expired - Fee Related
- 2003-04-21 ES ES06018822T patent/ES2399900T3/es not_active Expired - Lifetime
- 2003-04-21 TW TW092109215A patent/TWI362932B/zh not_active IP Right Cessation
- 2003-04-21 BR BR0309390-5A patent/BR0309390A/pt not_active IP Right Cessation
- 2003-04-21 DE DE60315939T patent/DE60315939T2/de not_active Expired - Lifetime
- 2003-04-21 NZ NZ535970A patent/NZ535970A/en not_active IP Right Cessation
- 2003-04-21 MX MXPA04010311A patent/MXPA04010311A/es active IP Right Grant
- 2003-04-21 EP EP06018822A patent/EP1741433B1/en not_active Expired - Lifetime
- 2003-04-21 KR KR1020097013431A patent/KR100977896B1/ko not_active Expired - Fee Related
- 2003-04-21 CA CA002470200A patent/CA2470200C/en not_active Expired - Fee Related
- 2003-04-21 PL PL372083A patent/PL213976B1/pl unknown
- 2003-04-21 DK DK03726373T patent/DK1425019T3/da active
- 2003-04-21 AT AT03726373T patent/ATE371456T1/de active
- 2003-04-21 KR KR1020047016828A patent/KR100952786B1/ko not_active Expired - Fee Related
- 2003-04-21 WO PCT/US2003/012235 patent/WO2003088974A1/en not_active Ceased
- 2003-04-21 ES ES03726373T patent/ES2292964T3/es not_active Expired - Lifetime
- 2003-04-21 JP JP2003585726A patent/JP2005519985A/ja active Pending
- 2003-04-21 AR ARP030101362A patent/AR039644A1/es not_active Application Discontinuation
- 2003-04-21 EP EP03726373A patent/EP1425019B1/en not_active Expired - Lifetime
- 2003-04-21 CN CN201110259341.7A patent/CN102357098B/zh not_active Expired - Fee Related
- 2003-06-22 SA SA03240158A patent/SA03240158B1/ar unknown
2004
- 2004-10-13 IL IL164547A patent/IL164547A/en not_active IP Right Cessation
- 2004-10-18 ZA ZA200408422A patent/ZA200408422B/en unknown
- 2004-10-27 LV LVP-04-127A patent/LV13303B/en unknown
- 2004-11-17 IS IS7535A patent/IS2667B/is unknown
- 2004-11-18 LT LT2004101A patent/LT5235B/lt not_active IP Right Cessation
- 2004-11-18 NO NO20045019A patent/NO335864B1/no not_active IP Right Cessation
2007
- 2007-10-30 US US11/929,610 patent/US20080103120A1/en not_active Abandoned
- 2007-10-30 US US11/928,467 patent/US7935690B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/930,812 patent/US8063029B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,809 patent/US8178518B2/en not_active Expired - Fee Related
- 2007-11-26 CY CY20071101504T patent/CY1109005T1/el unknown
2009
- 2009-01-20 US US12/356,515 patent/US7608606B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/356,513 patent/US7608605B2/en not_active Expired - Fee Related
- 2009-01-21 US US12/356,943 patent/US7608607B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,162 patent/US7608608B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,183 patent/US7608609B2/en not_active Expired - Fee Related
- 2009-02-02 US US12/364,413 patent/US7608610B2/en not_active Expired - Fee Related
- 2009-03-19 US US12/407,460 patent/US20090192132A1/en not_active Abandoned
- 2009-03-19 US US12/407,418 patent/US20090192131A1/en not_active Abandoned
- 2009-09-30 US US12/570,847 patent/US20100081640A1/en not_active Abandoned
2010
- 2010-01-06 IS IS8870A patent/IS2946B/is unknown
2012
- 2012-04-11 US US13/444,637 patent/US20210308145A1/en not_active Abandoned
- 2012-08-03 US US13/566,633 patent/US20210308146A1/en not_active Abandoned
- 2012-08-08 AR ARP120102894A patent/AR087484A2/es unknown
- 2012-08-31 US US13/601,572 patent/US20130059828A1/en not_active Abandoned
2013
- 2013-06-19 US US13/921,879 patent/US20130281416A1/en not_active Abandoned
2014
- 2014-03-04 US US14/196,705 patent/US20140343025A1/en not_active Abandoned
2015
- 2015-04-07 US US14/680,197 patent/US20150283153A1/en not_active Abandoned
2016
- 2016-01-19 US US15/000,848 patent/US20160129016A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60315939D1 (de)	2007-10-11
US20130059828A1 (en)	2013-03-07
EA200401410A1 (ru)	2005-04-28
WO2003088974A1 (en)	2003-10-30
CA2470200C (en)	2005-07-26
US20080275012A1 (en)	2008-11-06
TW200408397A (en)	2004-06-01
US20100081640A1 (en)	2010-04-01
US20090124589A1 (en)	2009-05-14
US20090131387A1 (en)	2009-05-21
EP1425019A1 (en)	2004-06-09
HK1098386A1 (en)	2007-07-20
US7608609B2 (en)	2009-10-27
US20130281416A1 (en)	2013-10-24
US7608606B2 (en)	2009-10-27
BR0309390A (pt)	2005-02-09
HK1167332A1 (en)	2012-11-30
CN102357098B (zh)	2014-12-17
US20090192131A1 (en)	2009-07-30
IS8870A (is)	2010-01-06
EP1741433B1 (en)	2012-11-07
KR100977896B1 (ko)	2010-08-24
US20160129016A1 (en)	2016-05-12
US7608610B2 (en)	2009-10-27
MXPA04010311A (es)	2005-02-03
DK1425019T3 (da)	2008-02-04
AR087484A2 (es)	2014-03-26
AR039644A1 (es)	2005-03-02
US20090118250A1 (en)	2009-05-07
CN1662243A (zh)	2005-08-31
MY139721A (en)	2009-10-30
CA2470200A1 (en)	2003-10-30
SA03240158B1 (ar)	2007-02-17
US20090124590A1 (en)	2009-05-14
NZ535970A (en)	2006-12-22
US20090118252A1 (en)	2009-05-07
US8063029B2 (en)	2011-11-22
US20080275013A1 (en)	2008-11-06
US20050192260A1 (en)	2005-09-01
TWI362932B (en)	2012-05-01
ES2292964T3 (es)	2008-03-16
KR20090079266A (ko)	2009-07-21
DE60315939T2 (de)	2008-05-21
CY1109005T1 (el)	2014-07-02
LV13303B (en)	2006-08-20
KR100952786B1 (ko)	2010-04-14
US7608605B2 (en)	2009-10-27
HK1082682A1 (en)	2006-06-16
US7320968B2 (en)	2008-01-22
EP1425019B1 (en)	2007-08-29
AU2003228612B2 (en)	2006-05-04
CN102357098A (zh)	2012-02-22
JP2005519985A (ja)	2005-07-07
US20210308146A1 (en)	2021-10-07
NO335864B1 (no)	2015-03-09
US20090118251A1 (en)	2009-05-07
LT5235B (lt)	2005-06-27
US20140343025A1 (en)	2014-11-20
US7608607B2 (en)	2009-10-27
US20080103120A1 (en)	2008-05-01
US7608608B2 (en)	2009-10-27
PL372083A1 (en)	2005-07-11
ES2399900T3 (es)	2013-04-04
US20210308145A1 (en)	2021-10-07
IL164547A0 (en)	2005-12-18
EP1425019A4 (en)	2004-11-17
NO20045019L (no)	2005-01-14
IS2667B (is)	2010-08-15
LT2004101A (en)	2005-04-25
IS2946B (is)	2016-05-15
AU2003228612A1 (en)	2003-11-03
IL164547A (en)	2011-01-31
US20090192132A1 (en)	2009-07-30
US20080108590A1 (en)	2008-05-08
US7935690B2 (en)	2011-05-03
KR20050011753A (ko)	2005-01-29
EG24882A (en)	2010-12-01
PL213976B1 (pl)	2013-05-31
CN1662243B (zh)	2011-10-26
ZA200408422B (en)	2006-06-28
ATE371456T1 (de)	2007-09-15
US8178518B2 (en)	2012-05-15
EA009839B1 (ru)	2008-04-28
EP1741433A1 (en)	2007-01-10
US20150283153A1 (en)	2015-10-08

Publication	Publication Date	Title
IS7535A (is)	2004-11-17	Lyfjablanda
HUP0203056A1 (hu)	2002-12-28	Vakcinakészítmény
HRP20040059B1 (hr)	2008-05-31	Tretman infekcije nokta s no
ATE387191T1 (de)	2008-03-15	Kaubare weichkapsel
AU2003275958A1 (en)	2005-03-10	Muteins of tear lipocalin
SE0001899D0 (sv)	2000-05-22	New compounds
WO2005012530A3 (en)	2005-05-12	Antagonists and agonists of ldcam and methods of use
SG146648A1 (en)	2008-10-30	Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2004024300A8 (en)	2004-12-16	Ultrafiltration membrane, device, bioartificial organ and methods
ATE312635T1 (de)	2005-12-15	Ventilanordnung
NO20042596L (no)	2004-06-21	Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE59410052D1 (de)	2002-03-21	Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
WO2003099110A3 (en)	2004-06-17	Herbs and herbal combinations useful for the treatment of microbial infections
HUP0303838A2 (hu)	2004-03-01	Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
DE602004015406D1 (de)	2008-09-11	Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
CO5660287A2 (es)	2006-07-31	Derivados de tetrahidrocarbazol y su uso farmaceutico
ATE404577T1 (de)	2008-08-15	Verfahren zur herstellung von eplerenon
ATE276006T1 (de)	2004-10-15	Teilbare hüllenanordnung mit okklusionsballon
WO2002070638A3 (en)	2003-12-18	Essential oil from.coleus forskohlii, production process and use as antimicrobial agent
JO2545B1 (en)	2010-09-05	Pharmaceutical compound
DE60142786D1 (de)	2010-09-23	Zusammensetzungen und methoden zur behandlung von candidosen
CY1114137T1 (el)	2016-07-27	Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο
PH12022551079A1 (en)	2024-06-19	Accelerated tissue dissolution
DE60229624D1 (de)	2008-12-11	Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE60305018D1 (de)	2006-06-08	Citalopram zur behandlung von bluthochdruck